IL110855A - Methods for inducing antigen-specific t cell tolerance - Google Patents

Methods for inducing antigen-specific t cell tolerance

Info

Publication number
IL110855A
IL110855A IL11085594A IL11085594A IL110855A IL 110855 A IL110855 A IL 110855A IL 11085594 A IL11085594 A IL 11085594A IL 11085594 A IL11085594 A IL 11085594A IL 110855 A IL110855 A IL 110855A
Authority
IL
Israel
Prior art keywords
cell
methods
antigen
receptor
tolerance
Prior art date
Application number
IL11085594A
Other languages
English (en)
Other versions
IL110855A0 (en
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL110855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of IL110855A0 publication Critical patent/IL110855A0/xx
Publication of IL110855A publication Critical patent/IL110855A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL11085594A 1993-09-02 1994-09-02 Methods for inducing antigen-specific t cell tolerance IL110855A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11625593A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (2)

Publication Number Publication Date
IL110855A0 IL110855A0 (en) 1994-11-28
IL110855A true IL110855A (en) 1999-04-11

Family

ID=26814047

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11085594A IL110855A (en) 1993-09-02 1994-09-02 Methods for inducing antigen-specific t cell tolerance

Country Status (17)

Country Link
US (5) US5747037A (fr)
EP (2) EP0721469B1 (fr)
JP (3) JP3007977B2 (fr)
CN (2) CN1127351C (fr)
AT (2) ATE188487T1 (fr)
AU (2) AU696235B2 (fr)
DE (2) DE69422523T2 (fr)
DK (2) DK0721469T3 (fr)
ES (2) ES2120067T3 (fr)
FI (2) FI105528B (fr)
GR (2) GR3027658T3 (fr)
HU (2) HU220296B (fr)
IL (1) IL110855A (fr)
NO (2) NO321036B1 (fr)
NZ (3) NZ549136A (fr)
PT (1) PT721469E (fr)
WO (2) WO1995006481A1 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
WO1995006481A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
DE19634159C1 (de) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Injektion von Hybridzellen
WO1998008541A1 (fr) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition de la reaction immunitaire primaire et/ou secondaire a l'administration repetee d'un vecteur adenoviral au moyen d'anticorps specifiques de cd40l
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
AU780031B2 (en) 1998-12-14 2005-02-24 Genetics Institute, Llc Cytokine receptor chain
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU2845400A (en) * 1998-12-24 2000-07-31 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
EP1101495A4 (fr) * 1999-06-01 2003-05-07 Eisai Co Ltd Agents prophylactiques du purpura thrombocytopenique idiopathique
AU5641100A (en) * 1999-06-29 2001-01-31 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1262194A4 (fr) * 2000-03-06 2003-05-07 Eisai Co Ltd Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
WO2001079555A2 (fr) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles des membres de la famille jak/stat dans l'induction de la tolerance
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
CA2410188A1 (fr) * 2000-06-06 2001-12-13 Idec Pharmaceutical Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
TWI322153B (en) 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2002220165A1 (en) * 2000-11-14 2002-05-27 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
WO2004003019A2 (fr) * 2002-06-28 2004-01-08 Domantis Limited Ligand
EP2075256A2 (fr) 2002-01-14 2009-07-01 William Herman Ligands ciblés
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2003220820A1 (en) * 2002-04-03 2003-10-27 Eisai Co., Ltd. Remedies for pemphigus containing cd40l antagonist as the active ingredient
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
SG10201900535UA (en) * 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
WO2006033702A2 (fr) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anticorps anti-cd154
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1851308B1 (fr) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Lymphocytes t cd4+ cd25+ activés par un antigène spécifique
CN100423775C (zh) * 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 牛衣原体病灭活疫苗及其制备与检验方法
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
CA2646329C (fr) * 2006-03-20 2018-07-03 The Regents Of The University Of California Anticorps modifies diriges contre l'antigene de cellules souches prostatiques servant a cibler le cancer
MX363905B (es) * 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
EP2197491A4 (fr) 2007-09-04 2011-01-12 Univ California Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
EP2052848A1 (fr) 2007-10-27 2009-04-29 Joint Solar Silicon GmbH & Co. KG Préparation de pièces brutes en silicium pur
EP2132228B1 (fr) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Produits d immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
WO2010093467A1 (fr) 2009-02-10 2010-08-19 The Trustees Of Columbia University In The City Of New York Méthodes pour induire une tolérance à la transplantation
WO2013013708A1 (fr) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Traitement du rejet aigu dans une transplantation rénale
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
WO2015038888A1 (fr) 2013-09-13 2015-03-19 Genentech, Inc. Procédés et compositions comprenant des polypeptides recombinants purifiés
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MX2018000548A (es) 2015-07-14 2018-09-26 Immunext Inc Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
CA2946465C (fr) 2015-11-12 2022-03-29 Delta Faucet Company Generateur d'ozone destine a un robinet
WO2018217918A2 (fr) 2017-05-24 2018-11-29 Als Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
WO1995006481A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
AU678532B2 (en) 1997-05-29
FI960980A (fi) 1996-04-30
EP0721469B1 (fr) 2000-01-05
FI960978A (fi) 1996-04-29
DE69411025D1 (de) 1998-07-16
NO321036B1 (no) 2006-03-06
CN1127351C (zh) 2003-11-12
US7722874B2 (en) 2010-05-25
HU9600522D0 (en) 1996-04-29
DK0721346T3 (da) 1999-03-22
JPH11189543A (ja) 1999-07-13
EP0721346B1 (fr) 1998-06-10
NO321098B1 (no) 2006-03-20
NO960862L (no) 1996-04-30
HU9600521D0 (en) 1996-04-29
US20060222649A1 (en) 2006-10-05
DE69411025T2 (de) 1999-01-07
AU7642994A (en) 1995-03-22
CN1149299A (zh) 1997-05-07
US6312692B1 (en) 2001-11-06
AU696235B2 (en) 1998-09-03
JP3007977B2 (ja) 2000-02-14
US5747037A (en) 1998-05-05
NO960862D0 (no) 1996-03-01
HU218610B (hu) 2000-10-28
WO1995006481A1 (fr) 1995-03-09
NZ273221A (en) 2001-09-28
WO1995006666A1 (fr) 1995-03-09
AU7644594A (en) 1995-03-22
FI960978A0 (fi) 1996-03-01
HUT74246A (en) 1996-11-28
US5876718A (en) 1999-03-02
NO960861D0 (no) 1996-03-01
JP2991499B2 (ja) 1999-12-20
US20020187135A1 (en) 2002-12-12
CN100341896C (zh) 2007-10-10
JP3098739B2 (ja) 2000-10-16
ES2120067T3 (es) 1998-10-16
ATE167062T1 (de) 1998-06-15
JPH09502096A (ja) 1997-03-04
AU707110B2 (en) 1999-07-01
DE69422523T2 (de) 2000-10-12
ATE188487T1 (de) 2000-01-15
CN1134113A (zh) 1996-10-23
FI106306B (fi) 2001-01-15
EP0721469A1 (fr) 1996-07-17
GR3027658T3 (en) 1998-11-30
AU3518397A (en) 1997-10-30
HU220296B (hu) 2001-11-28
NZ273207A (en) 1997-09-22
HUT74250A (en) 1996-11-28
NZ549136A (en) 2008-02-29
JPH09502186A (ja) 1997-03-04
ES2143553T3 (es) 2000-05-16
PT721469E (pt) 2000-04-28
GR3033095T3 (en) 2000-08-31
FI960980A0 (fi) 1996-03-01
IL110855A0 (en) 1994-11-28
FI105528B (fi) 2000-09-15
NO960861L (no) 1996-04-30
EP0721346A1 (fr) 1996-07-17
DK0721469T3 (da) 2000-05-01
DE69422523D1 (de) 2000-02-10

Similar Documents

Publication Publication Date Title
IL110855A0 (en) Methods for inducing antigen-specific T cell tolerance
WO1995028957A3 (fr) Procedes servant a provoquer la tolerance des lymphocytes t a une greffe de tissu ou d'organe
DE69435171D1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
KR960704575A (ko) 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance)
AU2003214076A1 (en) Method for isolating ligands eg T cell epitopes
HK1002012A1 (en) Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
Mariotti et al. The autoimmune infiltrate of Basedow's disease: analysis at clonal level and comparison with Hashimoto's thyroiditis
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central
Luciani et al. Self-sparing of long-term in vitro-cloned or uncloned cytotoxic T lymphocytes.
Tuttosi et al. Antigen-specific CD8+ T cells switch the immune response induced by antigen from an IgG to a cell-mediated mode.
Matsushita et al. Clonal expansion of freshly isolated CD4T cells by randomized peptides and identification of peptide ligands using combinatorial peptide libraries
Roehm et al. Helper signals in B lymphocyte differentiation
MX9605051A (es) Metodos para inducir la tolerancia de celulas t a un injerto u organo.
AU1638399A (en) Scid mouse having human immune response
Bass Two types of T helper cells in mice: Differences in cellular immune functions and cytokine secretion--selective reduction of one type after total lymphoid irradiation
WO2001002005A3 (fr) Induction de la tolerance immunitaire
CA2311679A1 (fr) Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees